# Assertio (ASRT) Stock Price, News & Catalysts
Canonical URL: https://biopharmsignal.com/company/ASRT
## Company Profile
- Ticker: ASRT
- Exchange: NASDAQ
- Sector: Biopharma
- Location: United States
- Tags: CNS
## Stock Data
- Close: 23.5 USD
- Market cap: 151538121 USD
- Last updated: 2026-06-15
## Business Overview
### Specialty Pharmaceutical Company
Assertio Holdings commercializes differentiated prescription products, with its current strategy centered primarily on oncology supportive care. The company has assembled its portfolio through acquisitions and licensing transactions and operates commercial, market-access, trade, and distribution capabilities.
### Rolvedon Oncology Franchise
Rolvedon, or eflapegrastim-xnst, is a long-acting granulocyte colony-stimulating factor used to reduce the incidence of infection manifested by febrile neutropenia in adults receiving myelosuppressive anticancer therapy. It is the company's lead product and is promoted to both hospital systems and community oncology practices.
### Sympazan Neurology Product
Sympazan is an oral film formulation of clobazam used as adjunctive treatment for seizures associated with Lennox-Gastaut syndrome in patients aged two years and older. The film adheres to the tongue and can serve patients who have difficulty swallowing conventional tablets or liquids.
### Hospital and Pain Products
The remaining marketed portfolio includes INDOCIN formulations, SPRIX ketorolac nasal spray, and CAMBIA diclofenac oral solution. These products address hospital, acute-pain, migraine, and inflammatory-care settings, although they are less central to the company's current oncology-focused strategy.
### Acquisition-Led Commercial Model
Assertio seeks approved or late-stage products that can be supported through its existing infrastructure. Centralized commercialization and portfolio integration allow the company to manage products across multiple specialty channels without operating a broad internal research platform.
## Why The Stock Is Moving

Current closing-price context is not available for ASRT.

## Recent News
- 2025-10-28 13:15 EST — [Assertio Announces Leadership Transition](https://biopharmsignal.com/news/ASRT/assertio-announces-leadership-transition-13208d9d) — Source: Assertio
- 2025-09-15 13:00 EST — [Assertio Presents First-Ever Real-World Study Showing Patient Experience with SYMPAZAN® (clobazam) Oral Film, CIV](https://biopharmsignal.com/news/ASRT/assertio-presents-first-ever-real-world-study-showing-patient-experience-with-sy-14523696) — Source: Assertio
- 2025-09-10 11:30 EST — [Assertio to Present New Data from Real-World Evidence Study of SYMPAZAN® at upcoming 150th Annual Meeting of the American Neurological Association](https://biopharmsignal.com/news/ASRT/assertio-to-present-new-data-from-real-world-evidence-study-of-sympazan-at-upcom-a319cbba) — Source: Assertio
- 2025-09-03 12:15 EST — [Assertio to Participate in the HC Wainwright and Lake Street Conferences in September 2025](https://biopharmsignal.com/news/ASRT/assertio-to-participate-in-the-hc-wainwright-and-lake-street-conferences-in-sept-8cca2126) — Source: Assertio
- 2025-08-11 20:05 EST — [Assertio Reports Second Quarter 2025 Financial Results](https://biopharmsignal.com/news/ASRT/assertio-reports-second-quarter-2025-financial-results-d87a0872) — Source: Assertio